CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dyax Corp. (Nasdaq:DYAX) announced today that the United States Patent and Trademark office has issued two U.S. Patents relating to its program for on-pump cardiothoracic surgery (CTS). U.S. Patent No. 7,153,829 (issued December 26, 2006) covers methods for preventing or reducing perioperative blood loss due to surgery by administering its proprietary kallikrein inhibitor, DX-88 (ecallantide), as well as methods for preventing or reducing reperfusion injury with DX-88. U.S. Patent No. 7,064,107 (issued June 20, 2006) covers methods for preventing or reducing ischemia or systemic inflammatory response associated with surgery by administering a kallikrein inhibitor. The new patents provide Dyax with claims that directly cover the company’s CTS program.
